Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors. (nejm.org)

Authors: Dumbrava EE … Schram AM Journal: New England Journal of Medicine Published: 2026-02-26 DOI: https://doi.org/10.1056/NEJMoa2508820